Original ArticleNon–Small Cell Lung CancerCombined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study
Keywords
Cited by (0)
Disclosure: Dr. Jänne reports receiving grants and research support from Astellas and AstraZeneca; receiving consulting fees from Astra Zeneca, Roche, Genentech, Merrimack, Chugai, and Clovis Oncology; and holding stock in Gatekeeper. Dr. Shaw reports receiving grants and personal fees from Pfizer, Novartis, Ariad, Chugai, Genentech, Daiichi-Sankyo, and Ignyta. Dr. Camidge reports receiving consulting fees from Pfizer. Drs. Shreeve, Tang, Goldberg, Martini, Xu, and James were employees of Pfizer at the time this work was conducted and held Pfizer stock. Dr. Solomon reports receiving consulting fees from Pfizer, Novartis, Roche, Merck Sharpe & Dohme, AstraZeneca, and BMS; receiving research funding from Pfizer; holding patent/intellectual property with Biodesix; and receiving travel, accommodation, and other expenses from Roche and AstraZeneca. The remaining author declares no conflict of interest.